Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech Inhibitex
So what: Last week, Inhibitex shares got crushed when fellow drugmaker Pharmasset
Now what: Canaccord analyst George Farmer believes the sell-off was an overreaction and recommends aggressively buying the shares, while the company has assigned a price target of $22 to complement its rating. The $22 price target represents more than double Friday's close of $10.45, and even a healthy 91% higher than today's high so far of $11.49. Farmer believes the Street is factoring in higher risks with INX-189, which he believes is presenting an attractive entry point.
Interested in more info on Inhibitex? Add it to your watchlist by clicking here.